Track topics on Twitter Track topics that are important to you
Iridex reported $10.2 million in revenue in the fourth quarter of 2017, an 18% decrease compared with $12.5 million in 2016’s fourth quarter, the company announced in a press release.
The difference was attributed to a voluntary recall of the TruFocus LIO Premiere laser accessory, but it was offset by revenue from Cyclo G6 laser system and probe shipments, the release said.
Net loss for the quarter was $5.2 million compared with $10.8 million in the fourth quarter of 2016.
For the full year, revenue decreased 10% to $41.6 million compared with $46.2 million in 2016.
Yearly net loss was
Original Article: Iridex revenue decreases in 2017NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...